Physical functioning is significantly diminished by intensive management of childhood posterior fossa brain tumors (PFTs) and correlates with survivors’ neurologic treatment burdens, suggests research presented at the 51st Annual ONS Congress in San Antonio, Texas. Read more: https://www.oncologynurseadvisor.com/reports/brain-tumors-functional-challenges-long-term-pediatric-pft/

In a study published in Cell Death & Disease, researchers led by Blanco identified a potential way to reduce relapse in medulloblastoma by targeting the tumor cells most likely to survive treatment and drive regrowth. Read more: https://www.news-medical.net/news/20260526/Scientists-target-root-of-relapse-in-aggressive-childhood-brain-tumors.aspx

A team of scientists has uncovered new evidence that some cases of a subtype of childhood leukaemia may develop before birth, shedding light on how the disease evolves over time. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/new-study-traces-rare-form-of-childhood-leukaemia-back-to-before-birth

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumour types. Read more: https://www.eurekalert.org/news-releases/1129340

Pediatric Non-Hispanic Black patients with acute myeloid leukemia (AML) are at increased risk for acute kidney injury (AKI) during treatment, according to research published in Cancer Medicine. Read more: https://www.cancertherapyadvisor.com/news/pediatric-non-hispanic-black-aml-all-patients-acute-kidney-injury/

When young people are diagnosed with cancer, proton therapy helps preserve what matters. Read more: https://www.fredhutch.org/en/news/blog/2026/05/fertility-and-other-considerations-when-treating-cancer-in-adolescents-and-young-adults.html

Most anticancer drugs that enter clinical testing in children and adolescents fail to reach late-phase trials or earn pediatric regulatory approval, according to the authors of new research. Read more: https://www.medscape.com/viewarticle/few-pediatric-cancer-drugs-reach-phase-3-or-approval-2026a1000fsh?src=rss&form=fpf

New research has endorsed a long‑standing idea explaining why acute lymphoblastic leukaemia (ALL) – the most common cancer in children – appears abruptly in early life, often in otherwise healthy individuals, with no obvious environmental trigger. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/childhood-leukaemia-and-germs--research-reveals-the-critical-importance-of-timing

Researchers investigating neuroblastoma – a cancer that primarily affects babies and children under five – have discovered that tetracaine, a long‑established local anaesthetic, can significantly suppress the cancer cells’ ability to invade surrounding tissue in laboratory experiments. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/local-anaesthetic-shows-promise-in-blocking-childhood-cancer-spread--study-finds

For pediatric brain tumor survivors (PBTS), the necessity and challenge of sustaining meaningful friendships is more pronounced due to differences in social, emotional and neurocognitive abilities, areas collectively called psychosocial functioning. Read more: https://www.stjude.org/research/progress/2026/understanding-best-friendships-and-psychosocial-health-in-pediatric-brain-tumor-survivors.html